Related references
Note: Only part of the references are listed.A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors
S. Sharma et al.
ANNALS OF ONCOLOGY (2010)
Antiangiogenesis agents in colorectal cancer
Joleen Hubbard et al.
CURRENT OPINION IN ONCOLOGY (2010)
A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer
Sang Joon Shin et al.
INVESTIGATIONAL NEW DRUGS (2010)
Evolving Treatment of Advanced Colorectal Cancer
Andrea Cercek et al.
CURRENT ONCOLOGY REPORTS (2010)
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine
Smitha S. Krishnamurthi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer
F. Caponigro et al.
EUROPEAN JOURNAL OF CANCER (2009)
Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401
Pasquale Comella et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
Carbamate Analogues of Fumagillin as Potent, Targeted Inhibitors of Methionine Aminopeptidase-2
Christopher C. Arico-Muendel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
M. L. Rothenberg et al.
ANNALS OF ONCOLOGY (2008)
Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials
Hendrik-Tobias Arkenau et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
Jim Cassidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer:: Final report of the Spanish cooperative group for the treatment of digestive tumors trial
Eduardo Diaz-Rubio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO colorectal study group
Rainer Porschen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings
Bruce J. Giantonio
SEMINARS IN ONCOLOGY (2006)
OPTIMOX1:: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer -: A GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors
O Soepenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients
J Liu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer
MM Borner et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
E Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
PM Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Clinical pharmacokinetics of capecitabine
B Reigner et al.
CLINICAL PHARMACOKINETICS (2001)
Share Paper
